Clinical trial
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
NCT00424021 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00424021 |
|---|---|
| Title | Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension |
| Official title | An Open-Label, Long-Term Study of Ambrisentan in Pulmonary Hypertension Subjects Having Completed Myogen Study AMB-220 |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | ambrisentan |
| Enrollment | 54 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jan 18, 2007 |
| Last update posted | Jan 27, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: